Abbvie patents expiration
1. Acular Ls patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8008338 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8648107 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(a month from now) | |
| US8906950 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(a month from now) | |
| US8541463 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(a month from now) | |
| US8377982 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(a month from now) | |
| US8207215 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(a month from now) | |
| US8946281 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(a month from now) | |
| US9216167 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(a month from now) | |
| US9216127 | ABBVIE | Burial vault and method for customizing a burial vault |
May, 2024
(a month from now) | |
|
US8541463 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(7 months from now) | |
|
US8377982 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(7 months from now) | |
|
US8207215 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(7 months from now) | |
|
US8008338 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2027
(3 years from now) | |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: A method of treating or preventing ocular pain and burning; A method of treating or reducing ocular pain and burning/stinging; A method of treating or preventing ocular pain and burning/stinging follo...
Dosage: SOLUTION/DROPS;OPHTHALMIC
ACULAR LS family patents
2. Acuvail patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7842714 | ABBVIE | Ketorolac tromethamine compositions for treating ocular pain |
Aug, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8992952 | ABBVIE | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Aug, 2024
(3 months from now) | |
| US8512717 | ABBVIE | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Mar, 2028
(3 years from now) | |
| US9192571 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 22, 2012 |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 22 July, 2009
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
ACUVAIL family patents
3. Aczone patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5863560 | ABBVIE | Compositions and methods for topical application of therapeutic agents |
Sep, 2016
(7 years ago) | |
| US6620435 | ABBVIE | Compositions for topical application of therapeutic agents |
Sep, 2016
(7 years ago) | |
| US6060085 | ABBVIE | Compositions and methods for topical application of therapeutic agents |
Sep, 2016
(7 years ago) | |
Drugs and Companies using DAPSONE ingredient
Market Authorisation Date: 07 July, 2005
Treatment: Treatment of acne
Dosage: GEL;TOPICAL
ACZONE family patents
4. Advicor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6676967 | ABBVIE | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
Sep, 2013
(10 years ago) | |
| US6129930 | ABBVIE | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
Sep, 2013
(10 years ago) | |
| US6406715 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
Sep, 2013
(10 years ago) | |
| US7998506 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
| US6818229 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
Sep, 2013
(10 years ago) | |
| US7011848 | ABBVIE | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
| US6746691 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
Sep, 2013
(10 years ago) | |
| US6080428 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
May, 2017
(6 years ago) | |
| US6469035 | ABBVIE | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
Mar, 2018
(6 years ago) | |
Drugs and Companies using LOVASTATIN; NIACIN ingredient
Market Authorisation Date: 17 December, 2001
Treatment: A method of reducing flush in an individual being treated for a lipidemic disorder and effectively treating the lipidemic disorder; Method of treating hyperlipidemia with nicotinic acid without causin...
Dosage: TABLET, EXTENDED RELEASE;ORAL
ADVICOR family patents
5. Alphagan P patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5424078 (Pediatric) | ABBVIE | Aqueous ophthalmic formulations and methods for preserving same |
Dec, 2012
(11 years ago) | |
| US9295641 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
| US6562873 | ABBVIE | Compositions containing therapeutically active components having enhanced solubility |
Jul, 2021
(2 years ago) | |
| US9687443 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
| US10307368 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
| US6627210 | ABBVIE | Compositions containing α-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
| US6673337 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
| US6641834 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jul, 2021
(2 years ago) | |
|
US6562873 (Pediatric) | ABBVIE | Compositions containing therapeutically active components having enhanced solubility |
Jan, 2022
(2 years ago) | |
|
US9687443 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
|
US9295641 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
|
US6627210 (Pediatric) | ABBVIE | Compositions containing α-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
|
US6673337 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
|
US6641834 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(2 years ago) | |
| US8858961 | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Sep, 2023
(7 months ago) | |
|
US8858961 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Mar, 2024
(a month ago) | |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 19 August, 2005
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
ALPHAGAN P family patents
6. Asacol Hd patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5541170 | ABBVIE | Orally administrable pharmaceutical compositions |
Jul, 2013
(10 years ago) | |
| US5541171 | ABBVIE | Orally administrable pharmaceutical composition |
Jul, 2013
(10 years ago) | |
| US6893662 | ABBVIE | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
Nov, 2021
(2 years ago) | |
| US9089492 | ABBVIE | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
Nov, 2021
(2 years ago) | |
| US8580302 | ABBVIE | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
Nov, 2021
(2 years ago) | |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 29 May, 2008
Treatment: Treatment of ulcerative colitis
Dosage: TABLET, DELAYED RELEASE;ORAL
ASACOL HD family patents
7. Biaxin Xl patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6010718 | ABBVIE | Extended release formulations of erythromycin derivatives |
Apr, 2017
(7 years ago) | |
| US6551616 | ABBVIE | Extended release formulations of erythromycin derivatives |
Jun, 2017
(6 years ago) | |
Drugs and Companies using CLARITHROMYCIN ingredient
Market Authorisation Date: 03 March, 2000
Treatment: Treatment of mild to moderate infection caused by susceptible strains
Dosage: TABLET, EXTENDED RELEASE;ORAL
BIAXIN XL family patents
8. Byvalson patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803838 | ABBVIE | Compositions comprising nebivolol |
Aug, 2026
(2 years from now) | |
| US7838552 | ABBVIE | Compositions comprising nebivolol |
Oct, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jun 03, 2019 |
Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient
Market Authorisation Date: 03 June, 2016
Treatment: Method of treating hypertension
Dosage: TABLET;ORAL
BYVALSON family patents
9. Calcijex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6051567 | ABBVIE | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
Aug, 2019
(4 years ago) | |
| US6274169 | ABBVIE | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
Aug, 2019
(4 years ago) | |
| US6265392 | ABBVIE | Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol |
Aug, 2019
(4 years ago) | |
|
US6051567 (Pediatric) | ABBVIE | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
Feb, 2020
(4 years ago) | |
|
US6274169 (Pediatric) | ABBVIE | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
Feb, 2020
(4 years ago) | |
|
US6265392 (Pediatric) | ABBVIE | Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol |
Feb, 2020
(4 years ago) | |
Drugs and Companies using CALCITRIOL ingredient
Market Authorisation Date: 25 September, 1986
Treatment: NA
Dosage: INJECTABLE;INJECTION
CALCIJEX family patents
10. Canasa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8217083 | ABBVIE | Mesalamine suppository |
Jun, 2028
(4 years from now) | |
| US8436051 | ABBVIE | Mesalamine suppository |
Jun, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Sep 02, 2019 |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 05 November, 2004
Treatment: NA
Dosage: SUPPOSITORY;RECTAL
CANASA family patents
11. Combigan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7642258 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9907801 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US9474751 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US9907802 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US7030149 | ABBVIE | Combination of brimonidine timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US8748425 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US8354409 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US8133890 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US9770453 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US7320976 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
| US7323463 | ABBVIE | Combination of brimonidine and timolol for topical ophthalmic use |
Jan, 2023
(1 year, 3 months ago) | |
Drugs and Companies using BRIMONIDINE TARTRATE; TIMOLOL MALEATE ingredient
Market Authorisation Date: 30 October, 2007
Treatment: Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with a reduction in specified adverse events, compared to brimonidine 0.2% tid; Reduction of elevated...
Dosage: SOLUTION/DROPS;OPHTHALMIC
COMBIGAN family patents
12. Creon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9198871 | ABBVIE | Delayed release pancreatin compositions |
Feb, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 30, 2014 |
| M(M-93) | Jul 29, 2019 |
| New Indication(I-625) | Apr 30, 2013 |
Drugs and Companies using PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) ingredient
NCE-1 date: 30 April, 2013
Market Authorisation Date: 30 April, 2009
Treatment: Treatment of exocrine pancreatic insufficiency
Dosage: CAPSULE, DELAYED RELEASE;ORAL
CREON family patents
13. Dalvance patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7115564 | ABBVIE | Stable pharmaceutical compositions of dalbavancin and methods of administration |
Nov, 2023
(5 months ago) | |
| US8143212 | ABBVIE | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(5 months ago) | |
| US7119061 | ABBVIE | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(5 months ago) | |
| US6900175 | ABBVIE | Methods of administering dalbavancin for treatment of bacterial infections |
May, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2019 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | May 23, 2024 |
| New Dosing Schedule(D-154) | Jan 20, 2019 |
Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 24 May, 2023
Market Authorisation Date: 23 May, 2014
Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.; Treatment of acute bacterial skin and skin structure infections (absssi) in adult and pediatric patients using a two-dose re...
Dosage: POWDER;INTRAVENOUS
DALVANCE family patents
14. Delzicol patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5541170 | ABBVIE | Orally administrable pharmaceutical compositions |
Jul, 2013
(10 years ago) | |
| US5541171 | ABBVIE | Orally administrable pharmaceutical composition |
Jul, 2013
(10 years ago) | |
| US6649180 | ABBVIE | Hard capsule formed of cellulose ether film with a specific content of methoxyl and hydroxypropoxyl groups |
Apr, 2020
(4 years ago) | |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 01 February, 2013
Treatment: Treatment of ulcerative colitis
Dosage: CAPSULE, DELAYED RELEASE;ORAL
DELZICOL family patents
15. Depakote Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6528090 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
| US6720004 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
| US6511678 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
| US6713086 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
| US6528091 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
| US6419953 | ABBVIE | Controlled release formulation of divalproex sodium |
Dec, 2018
(5 years ago) | |
|
US6713086 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
|
US6511678 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
|
US6528090 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
|
US6720004 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
|
US6419953 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
|
US6528091 (Pediatric) | ABBVIE | Controlled release formulation of divalproex sodium |
Jun, 2019
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Sep 24, 2011 |
Drugs and Companies using DIVALPROEX SODIUM ingredient
Market Authorisation Date: 31 May, 2002
Treatment: Treatment of epilepsy and/or migraine.; Treatment of epilepsy
Dosage: TABLET, EXTENDED RELEASE;ORAL
DEPAKOTE ER family patents
16. Durysta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8629185 | ABBVIE | 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof |
Jul, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7033605 | ABBVIE | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
| US10398707 | ABBVIE | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
Apr, 2024
(3 days from now) | |
| US8673341 | ABBVIE | Intraocular pressure reduction with intracameral bimatoprost implants |
Feb, 2025
(9 months from now) | |
| US10441543 | ABBVIE | Processes for making cyclic lipid implants for intraocular use |
Dec, 2026
(2 years from now) | |
| US9149428 | ABBVIE | Processes for making cyclic lipid implants for intraocular use |
Dec, 2026
(2 years from now) | |
| US8206737 | ABBVIE | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2027
(2 years from now) | |
| US7799336 | ABBVIE | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2029
(4 years from now) | |
| US9980974 | ABBVIE | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(10 years from now) | |
| US9492316 | ABBVIE | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 04, 2023 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 04 March, 2020
Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant
Dosage: IMPLANT;OPHTHALMIC
DURYSTA family patents
17. Enablex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5096890 | ABBVIE | Pyrrolidine derivatives |
Mar, 2015
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6106864 | ABBVIE | Pharmaceutical formulations containing darifenacin |
Aug, 2016
(7 years ago) | |
Drugs and Companies using DARIFENACIN HYDROBROMIDE ingredient
Market Authorisation Date: 22 December, 2004
Treatment: Treating urinary incontinence by administering an extended-release form of darifenacin; Treating a disease of altered motility or tone of smooth muscle by administering a muscarinic receptor antagoniz...
Dosage: TABLET, EXTENDED RELEASE;ORAL
ENABLEX family patents
18. Fetzima patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8865937 | ABBVIE | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide |
May, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE43879 | ABBVIE | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug |
Jan, 2026
(1 year, 8 months from now) | |
| US8481598 | ABBVIE | Stable dosage forms of levomilnacipran |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE*(NCE*) | Jul 25, 2018 |
| M(M-249) | Oct 07, 2022 |
Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient
Market Authorisation Date: 25 July, 2013
Treatment: Treatment of major depressive disorder (mdd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
FETZIMA family patents
19. Gelnique patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7029694 | ABBVIE | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US8241662 | ABBVIE | Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US7179483 | ABBVIE | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US10272061 | ABBVIE | Compositions and methods for unoccluded transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US10449173 | ABBVIE | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(5 years from now) | |
| US9259388 | ABBVIE | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(5 years from now) | |
| US8920392 | ABBVIE | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jan 27, 2012 |
Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient
Market Authorisation Date: 27 January, 2009
Treatment: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence; Treatment of patients with an overactive bladder with symptoms of urinary frequency,...
Dosage: GEL;TRANSDERMAL
GELNIQUE family patents
20. Kaletra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5541206 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
| US5886036 | ABBVIE | Retroviral protease inhibiting compounds |
Nov, 2013
(10 years ago) | |
| US5648497 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2014
(9 years ago) | |
| US5914332 | ABBVIE | Retroviral protease inhibiting compounds |
Dec, 2015
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5948436 | ABBVIE | Pharmaceutical composition |
Sep, 2013
(10 years ago) | |
| US5484801 | ABBVIE | Pharmaceutical composition for inhibiting HIV protease |
Jan, 2014
(10 years ago) | |
|
US5541206 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
|
US5948436 (Pediatric) | ABBVIE | Pharmaceutical composition |
Mar, 2014
(10 years ago) | |
|
US5886036 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
May, 2014
(9 years ago) | |
| US5648497 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2014
(9 years ago) | |
|
US5484801 (Pediatric) | ABBVIE | Pharmaceutical composition for inhibiting HIV protease |
Jul, 2014
(9 years ago) | |
|
US5648497 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2015
(9 years ago) | |
| US5914332 | ABBVIE | Retroviral protease inhibiting compounds |
Dec, 2015
(8 years ago) | |
| US6284767 | ABBVIE | Retroviral protease inhibiting compounds |
Feb, 2016
(8 years ago) | |
|
US5914332 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jun, 2016
(7 years ago) | |
| US6037157 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
| US6703403 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
|
US6284767 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Aug, 2016
(7 years ago) | |
|
US6037157 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
|
US6703403 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
| US6521651 | ABBVIE | Pharmaceutical composition |
Nov, 2017
(6 years ago) | |
| US6232333 | ABBVIE | Pharmaceutical composition |
Nov, 2017
(6 years ago) | |
| US6458818 | ABBVIE | Pharmaceutical composition |
Nov, 2017
(6 years ago) | |
|
US6521651 (Pediatric) | ABBVIE | Pharmaceutical composition |
May, 2018
(5 years ago) | |
|
US6458818 (Pediatric) | ABBVIE | Pharmaceutical composition |
May, 2018
(5 years ago) | |
|
US6232333 (Pediatric) | ABBVIE | Pharmaceutical composition |
May, 2018
(5 years ago) | |
| US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
|
US7148359 (Pediatric) | ABBVIE | Polymorph of a pharmaceutical |
Jan, 2020
(4 years ago) | |
| US7432294 | ABBVIE | Pharmaceutical formulations |
May, 2020
(3 years ago) | |
| US7141593 | ABBVIE | Pharmaceutical formulations |
May, 2020
(3 years ago) | |
| US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7432294 (Pediatric) | ABBVIE | Pharmaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7141593 (Pediatric) | ABBVIE | Pharmaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7364752 (Pediatric) | ABBVIE | Solid dispersion pharamaceutical formulations |
May, 2021
(2 years ago) | |
| US8501219 | ABBVIE | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
Nov, 2021
(2 years ago) | |
| US6911214 | ABBVIE | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
Nov, 2021
(2 years ago) | |
|
US6911214 (Pediatric) | ABBVIE | Flavoring systems for pharmaceutical compositions and methods of making such compositions |
May, 2022
(1 year, 10 months ago) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8691878 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8309613 | ABBVIE | Solid pharmaceutical dosage form |
Dec, 2024
(7 months from now) | |
|
US8691878 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
|
US8399015 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
|
US8268349 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
|
US8309613 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Jun, 2025
(1 year, 1 month from now) | |
| US8470347 | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Sep, 2026
(2 years from now) | |
|
US8470347 (Pediatric) | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Mar, 2027
(2 years from now) | |
| US8377952 | ABBVIE | Solid pharmaceutical dosage formulation |
Oct, 2027
(3 years from now) | |
| US8025899 | ABBVIE | Solid pharmaceutical dosage form |
Dec, 2027
(3 years from now) | |
|
US8377952 (Pediatric) | ABBVIE | Solid pharmaceutical dosage formulation |
Apr, 2028
(3 years from now) | |
|
US8025899 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Jun, 2028
(4 years from now) | |
Drugs and Companies using LOPINAVIR; RITONAVIR ingredient
Market Authorisation Date: 15 September, 2000
Treatment: Inhibiting protease with lopinavir and inhibiting an hiv infection with lopinavir; Treatment of hiv-infection in combination with other antiretroviral agents; Method for inhibiting cytochrome p450 mon...
Dosage: CAPSULE;ORAL; SOLUTION;ORAL; TABLET;ORAL
KALETRA family patents
21. Lastacaft patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5468743 | ABBVIE | Imidazo[2,1-b]benzazepine derivatives, compositions and method of use |
Apr, 2016
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10617695 | ABBVIE | Ophthalmic compositions containing alcaftadine |
Mar, 2027
(2 years from now) | |
| US8664215 | ABBVIE | Ocular allergy treatments with alcaftadine |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 28, 2015 |
Drugs and Companies using ALCAFTADINE ingredient
NCE-1 date: 28 July, 2014
Market Authorisation Date: 28 July, 2010
Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Dosage: SOLUTION/DROPS;OPHTHALMIC
LASTACAFT family patents
22. Latisse patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6403649 | ABBVIE | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Sep, 2012
(11 years ago) | |
| US8017655 | ABBVIE | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Nov, 2012
(11 years ago) | |
| US8038988 | ABBVIE | Method of enhancing hair growth |
Aug, 2023
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9579270 | ABBVIE | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan, 2021
(3 years ago) | |
| US8906962 | ABBVIE | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan, 2021
(3 years ago) | |
| US8541466 | ABBVIE | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan, 2021
(3 years ago) | |
| US7388029 | ABBVIE | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Jan, 2022
(2 years ago) | |
| US8263054 | ABBVIE | Method of enhancing hair growth |
Jan, 2023
(1 year, 3 months ago) | |
| US8632760 | ABBVIE | Method of enhancing hair growth |
Jan, 2023
(1 year, 3 months ago) | |
| US9226931 | ABBVIE | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(1 year, 3 months ago) | |
| US8758733 | ABBVIE | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(1 year, 3 months ago) | |
| US8986715 | ABBVIE | Method of enhancing hair growth |
Jan, 2023
(1 year, 3 months ago) | |
| US9216183 | ABBVIE | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(1 year, 3 months ago) | |
| US8926953 | ABBVIE | Method of enhancing hair growth |
Jan, 2023
(1 year, 3 months ago) | |
| US7351404 | ABBVIE | Method of enhancing hair growth |
May, 2024
(28 days from now) | |
| US8101161 | ABBVIE | Method of enhancing hair growth |
May, 2024
(28 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 24, 2011 |
| M(M-140) | Sep 04, 2017 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 24 December, 2008
Treatment: Method of increasing eyelash growth with bimatoprost; Method of increasing hair growth; Treatment of hair loss and hypotrichosis of the eyelashes by increasing their growth including length, thickness...
Dosage: SOLUTION/DROPS;TOPICAL
LATISSE family patents
23. Lexapro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6916941 | ABBVIE | Crystalline composition containing escitalopram |
Aug, 2022
(1 year, 8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7420069 | ABBVIE | Crystalline composition containing escitalopram |
Aug, 2022
(1 year, 8 months ago) | |
|
US6916941 (Pediatric) | ABBVIE | Crystalline composition containing escitalopram |
Feb, 2023
(1 year, 2 months ago) | |
|
US7420069 (Pediatric) | ABBVIE | Crystalline composition containing escitalopram |
Feb, 2023
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 12, 2026 |
Drugs and Companies using ESCITALOPRAM OXALATE ingredient
Market Authorisation Date: 14 August, 2002
Treatment: NA
Dosage: TABLET;ORAL
LEXAPRO family patents
24. Linzess patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7745409 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(2 months ago) | |
| US7704947 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(2 months ago) | |
| US8080526 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(2 months ago) | |
| US7371727 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(2 months ago) | |
| US7304036 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Aug, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8110553 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(2 months ago) | |
| US8933030 | ABBVIE | Treatments for gastrointestinal disorders |
Feb, 2031
(6 years from now) | |
| US10702576 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(7 years from now) | |
| US10675325 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(7 years from now) | |
| US8748573 | ABBVIE | Formulations comprising linaclotide |
Oct, 2031
(7 years from now) | |
| US8802628 | ABBVIE | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
Oct, 2031
(7 years from now) | |
| US9708371 | ABBVIE | Treatments for gastrointestinal disorders |
Aug, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-921) | Jun 12, 2026 |
| New Strength(NS) | Jan 25, 2020 |
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2017 |
Drugs and Companies using LINACLOTIDE ingredient
NCE-1 date: 30 August, 2016
Market Authorisation Date: 30 August, 2012
Treatment: Method of treating irritable bowel syndrome with constipation in adults; Treatment of functional constipation in pediatric patients 6 to 17 years of age; Method of treating chronic idiopathic constipa...
Dosage: CAPSULE;ORAL
LINZESS family patents
25. Lumigan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6403649 | ABBVIE | Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Sep, 2012
(11 years ago) | |
| US8017655 | ABBVIE | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Nov, 2012
(11 years ago) | |
| US7851504 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Jun, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5688819 | ABBVIE | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
Aug, 2014
(9 years ago) | |
| US8933127 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US8278353 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US9155716 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US8524777 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US9241918 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US8309605 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US8299118 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US8933120 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US8586630 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US8772338 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
| US8338479 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(10 months from now) | |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 16 March, 2001
Treatment: Lumigan is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; A method of lowering intraocular pressure; R...
Dosage: SOLUTION/DROPS;OPHTHALMIC
LUMIGAN family patents
26. Mavik patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5744496 | ABBVIE | Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors |
Apr, 2015
(9 years ago) | |
Drugs and Companies using TRANDOLAPRIL ingredient
Market Authorisation Date: 26 April, 1996
Treatment: Cardiac insufficiency (congestive heart failure)
Dosage: TABLET;ORAL
MAVIK family patents
27. Mavyret patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8648037 | ABBVIE | Macrocyclic proline derived HCV serine protease inhibitors |
Jan, 2032
(7 years from now) | |
| US8937150 | ABBVIE | Anti-viral compounds |
May, 2032
(8 years from now) | |
| USRE48923 | ABBVIE | Crystal forms |
May, 2035
(11 years from now) | |
| US9321807 | ABBVIE | Crystal forms |
Jun, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039754 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US10028937 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US9586978 | ABBVIE | Anti-viral compounds |
Nov, 2030
(6 years from now) | |
|
US10039754 (Pediatric) | ABBVIE | Anti-viral compounds |
Dec, 2030
(6 years from now) | |
|
US10028937 (Pediatric) | ABBVIE | Anti-viral compounds |
Dec, 2030
(6 years from now) | |
|
US9586978 (Pediatric) | ABBVIE | Anti-viral compounds |
May, 2031
(7 years from now) | |
|
US8648037 (Pediatric) | ABBVIE | Macrocyclic proline derived HCV serine protease inhibitors |
Jul, 2032
(8 years from now) | |
|
US8937150 (Pediatric) | ABBVIE | Anti-viral compounds |
Nov, 2032
(8 years from now) | |
| US10286029 | ABBVIE | Method for treating HCV |
Mar, 2034
(9 years from now) | |
| US11484534 | ABBVIE | Methods for treating HCV |
Mar, 2034
(9 years from now) | |
|
US10286029 (Pediatric) | ABBVIE | Method for treating HCV |
Sep, 2034
(10 years from now) | |
|
US11484534 (Pediatric) | ABBVIE | Methods for treating HCV |
Sep, 2034
(10 years from now) | |
|
USRE48923 (Pediatric) | ABBVIE | Crystal forms |
Nov, 2035
(11 years from now) | |
|
US9321807 (Pediatric) | ABBVIE | Crystal forms |
Dec, 2035
(11 years from now) | |
| US11246866 | ABBVIE | Solid pharmaceutical compositions for treating HCV |
Jun, 2036
(12 years from now) | |
|
US11246866 (Pediatric) | ABBVIE | Solid pharmaceutical compositions for treating HCV |
Dec, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-232) | Apr 30, 2026 |
| Orphan Drug Exclusivity(ODE-233) | Apr 30, 2026 |
| Orphan Drug Exclusivity(ODE-372) | Jun 10, 2028 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
| M(M-259) | Apr 10, 2023 |
| M(M-230) | Aug 06, 2021 |
| New Patient Population(NPP) | Apr 30, 2022 |
| New Dosing Schedule(D-175) | Sep 26, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 03, 2022 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 03 August, 2017
Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv)...
Dosage: TABLET;ORAL; PELLETS;ORAL
MAVYRET family patents
28. Namenda patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5061703 | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr, 2015
(9 years ago) | |
|
US5061703 (Pediatric) | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct, 2015
(8 years ago) | |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 October, 2003
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
Dosage: TABLET;ORAL
NAMENDA family patents
29. Namenda Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5061703 | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr, 2015
(9 years ago) | |
|
US5061703 (Pediatric) | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct, 2015
(8 years ago) | |
| US8329752 | ABBVIE | Composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
| US8283379 | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
| US8598233 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
| US8173708 | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
| US8362085 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
| US8168209 | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
|
US8173708 (Pediatric) | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8168209 (Pediatric) | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8598233 (Pediatric) | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8329752 (Pediatric) | ABBVIE | Composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8362085 (Pediatric) | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8283379 (Pediatric) | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
May, 2026
(2 years from now) | |
| US8039009 | ABBVIE | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(4 years from now) | |
|
US8039009 (Pediatric) | ABBVIE | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-138) | Jul 03, 2017 |
| Pediatric Exclusivity(PED) | Jan 03, 2018 |
| New Dosage Form(NDF) | Jun 21, 2013 |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 June, 2010
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
NAMENDA XR family patents
30. Namzaric patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5061703 | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr, 2015
(9 years ago) | |
|
US5061703 (Pediatric) | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct, 2015
(8 years ago) | |
| US8338486 | ABBVIE | Methods for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
| US8362085 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
| US8338485 | ABBVIE | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
| US8598233 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
| US8580858 | ABBVIE | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
| US8168209 | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
| US8293794 | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
| US8329752 | ABBVIE | Composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
| US8173708 | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
| US8283379 | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(1 year, 6 months from now) | |
|
US8168209 (Pediatric) | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8173708 (Pediatric) | ABBVIE | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8283379 (Pediatric) | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
May, 2026
(2 years from now) | |
|
US8598233 (Pediatric) | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8329752 (Pediatric) | ABBVIE | Composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
|
US8362085 (Pediatric) | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(2 years from now) | |
| US8039009 | ABBVIE | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(4 years from now) | |
|
US8039009 (Pediatric) | ABBVIE | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(5 years from now) | |
| US8058291 | ABBVIE | Methods and compositions for the treatment of CNS-related conditions |
Dec, 2029
(5 years from now) | |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 July, 2016
Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
NAMZARIC family patents
31. Niaspan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6676967 | ABBVIE | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
Sep, 2013
(10 years ago) | |
| US6746691 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
Sep, 2013
(10 years ago) | |
| US6406715 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
Sep, 2013
(10 years ago) | |
| US7998506 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
| US7011848 | ABBVIE | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
| US6129930 | ABBVIE | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
Sep, 2013
(10 years ago) | |
| US6818229 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
Feb, 2014
(10 years ago) | |
| US6080428 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
May, 2017
(6 years ago) | |
| US6469035 | ABBVIE | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
Mar, 2018
(6 years ago) | |
Drugs and Companies using NIACIN ingredient
Market Authorisation Date: 28 July, 1997
Treatment: A method of reducing flush in an individual being treated for a lipidemic disorder and effectively treating the lipidemic disorder; An intermediate release nicotinic acid formulation suitable for oral...
Dosage: TABLET, EXTENDED RELEASE;ORAL
NIASPAN family patents
32. Niaspan Titration Starter Pack patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7011848 | ABBVIE | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
| US6746691 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
Sep, 2013
(10 years ago) | |
| US6406715 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
Sep, 2013
(10 years ago) | |
| US6129930 | ABBVIE | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
Sep, 2013
(10 years ago) | |
| US6080428 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
May, 2017
(6 years ago) | |
Drugs and Companies using NIACIN ingredient
Market Authorisation Date: 28 July, 1997
Treatment: A method of using a nicotinic acid formulation to reduce elevated tc, ldl-c and tg levels, and raise hdl-c levels in patients with hyperlipidemia; An intermediate release nicotinic acid formulation su...
Dosage: TABLET, EXTENDED RELEASE;ORAL
NIASPAN TITRATION STARTER PACK family patents
33. Nimbex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5453510 | ABBVIE | Neuromuscular blocking agents |
Sep, 2012
(11 years ago) | |
Drugs and Companies using CISATRACURIUM BESYLATE ingredient
Market Authorisation Date: 15 December, 1995
Treatment: Method of producing neuromuscular blockade
Dosage: INJECTABLE;INJECTION
NIMBEX family patents
34. Nimbex Preservative Free patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5453510 | ABBVIE | Neuromuscular blocking agents |
Sep, 2012
(11 years ago) | |
Drugs and Companies using CISATRACURIUM BESYLATE ingredient
Market Authorisation Date: 15 December, 1995
Treatment: Method of producing neuromuscular blockade
Dosage: INJECTABLE;INJECTION
NIMBEX PRESERVATIVE FREE family patents
35. Norvir patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5541206 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
| US5648497 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2014
(9 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5541206 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
| US5635523 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
| US5674882 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2013
(10 years ago) | |
| US5948436 | ABBVIE | Pharmaceutical composition |
Sep, 2013
(10 years ago) | |
| US5484801 | ABBVIE | Pharmaceutical composition for inhibiting HIV protease |
Jan, 2014
(10 years ago) | |
|
US5541206 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
|
US5674882 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
|
US5635523 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2014
(10 years ago) | |
|
US5948436 (Pediatric) | ABBVIE | Pharmaceutical composition |
Mar, 2014
(10 years ago) | |
| US5648497 | ABBVIE | Retroviral protease inhibiting compounds |
Jul, 2014
(9 years ago) | |
|
US5484801 (Pediatric) | ABBVIE | Pharmaceutical composition for inhibiting HIV protease |
Jul, 2014
(9 years ago) | |
|
US5648497 (Pediatric) | ABBVIE | Retroviral protease inhibiting compounds |
Jan, 2015
(9 years ago) | |
| US6037157 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
| US6703403 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
|
US6037157 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
|
US6703403 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
| US6232333 | ABBVIE | Pharmaceutical composition |
Nov, 2017
(6 years ago) | |
|
US6232333 (Pediatric) | ABBVIE | Pharmaceutical composition |
May, 2018
(5 years ago) | |
| US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
|
US7148359 (Pediatric) | ABBVIE | Polymorph of a pharmaceutical |
Jan, 2020
(4 years ago) | |
| US7141593 | ABBVIE | Pharmaceutical formulations |
May, 2020
(3 years ago) | |
| US7432294 | ABBVIE | Pharmaceutical formulations |
May, 2020
(3 years ago) | |
| US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7432294 (Pediatric) | ABBVIE | Pharmaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7141593 (Pediatric) | ABBVIE | Pharmaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7364752 (Pediatric) | ABBVIE | Solid dispersion pharamaceutical formulations |
May, 2021
(2 years ago) | |
| US8691878 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
|
US8268349 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
|
US8691878 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
|
US8399015 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
| US8470347 | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Sep, 2026
(2 years from now) | |
|
US8470347 (Pediatric) | ABBVIE | Self-emulsifying active substance formulation and use of this formulation |
Mar, 2027
(2 years from now) | |
Drugs and Companies using RITONAVIR ingredient
Market Authorisation Date: 29 June, 1999
Treatment: Use of norvir to inhibit hiv protease or to inhibit an hiv infection; Treatment of hiv-infection in combination with other antiretroviral agents; Treatment of hiv infection in combination with other a...
Dosage: CAPSULE;ORAL; SOLUTION;ORAL; TABLET;ORAL
NORVIR family patents
36. Oriahnn (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6872728 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan, 2021
(3 years ago) | |
| US7462625 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan, 2021
(3 years ago) | |
| US7419983 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2024
(2 months from now) | |
| US7056927 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(4 months from now) | |
| US11542239 | ABBVIE | Elagolix sodium compositions and processes |
Jul, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7179815 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Mar, 2021
(3 years ago) | |
| US11459305 | ABBVIE | Processes for the preparation of uracil derivatives |
Nov, 2028
(4 years from now) | |
| US10881659 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(9 years from now) | |
| US11045470 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(9 years from now) | |
| US11690845 | ABBVIE | Methods of administering elagolix |
Aug, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
| New Product(NP) | May 29, 2023 |
NCE-1 date: 23 July, 2022
Market Authorisation Date: 29 May, 2020
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids); Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) using 300 mg elagolix while c...
Dosage: CAPSULE;ORAL
ORIAHNN (COPACKAGED) family patents
37. Orilissa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6872728 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan, 2021
(3 years ago) | |
| US7462625 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan, 2021
(3 years ago) | |
| US7419983 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2024
(2 months from now) | |
| US7056927 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(4 months from now) | |
| US11542239 | ABBVIE | Elagolix sodium compositions and processes |
Jul, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7179815 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Mar, 2021
(3 years ago) | |
| US7176211 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jul, 2024
(2 months from now) | |
| US11707464 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(9 years from now) | |
| US11344551 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(9 years from now) | |
| US10537572 | ABBVIE | Methods of administering elagolix |
Sep, 2036
(12 years from now) | |
| US10682351 | ABBVIE | Methods of administering elagolix |
Sep, 2036
(12 years from now) | |
| US11690854 | ABBVIE | Methods of treating heavy menstrual bleeding |
Apr, 2038
(13 years from now) | |
| US11690845 | ABBVIE | Methods of administering elagolix |
Aug, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: 23 July, 2022
Market Authorisation Date: 23 July, 2018
Treatment: Management of moderate to severe pain associated with endometriosis; Management of moderate to severe pain associated with endometriosis using 150 mg elagolix for up to 24 months; Use of elagolix 200 ...
Dosage: TABLET;ORAL
ORILISSA family patents
38. Oxytrol For Women patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5834010 | ABBVIE | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr, 2015
(9 years ago) | |
| US5601839 | ABBVIE | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
Apr, 2015
(9 years ago) | |
| US7081251 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US7081250 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US7081249 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US6743441 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US7081252 | ABBVIE | Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| US7179483 | ABBVIE | Compositions and methods for transdermal oxybutynin therapy |
Apr, 2020
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 25, 2016 |
Drugs and Companies using OXYBUTYNIN ingredient
Market Authorisation Date: 25 January, 2013
Treatment: Treatment of patients with an overactive bladder
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL FOR WOMEN family patents
39. Ozurdex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8063031 | ABBVIE | Implants and methods for treating inflammation-mediated conditions of the eye |
Oct, 2020
(3 years ago) | |
| US8043628 | ABBVIE | Methods for reducing edema |
Oct, 2020
(3 years ago) | |
| US8088407 | ABBVIE | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
| US6726918 | ABBVIE | Methods for treating inflammation-mediated conditions of the eye |
Oct, 2020
(3 years ago) | |
| US7033605 | ABBVIE | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
| US9012437 | ABBVIE | Implants and methods for treating inflammation-mediated conditions of the eye |
Oct, 2020
(3 years ago) | |
| US9592242 | ABBVIE | Methods for treating edema in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
| US9775849 | ABBVIE | Implants and methods for treating inflammation-mediated conditions of the eye |
Oct, 2020
(3 years ago) | |
| US9283178 | ABBVIE | Methods for treating edema in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
| US7767223 | ABBVIE | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use |
Nov, 2021
(2 years ago) | |
| US8034366 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US8034370 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US10702539 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US9192511 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US10076526 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US8506987 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US6899717 | ABBVIE | Methods and apparatus for delivery of ocular implants |
Nov, 2023
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jun 17, 2012 |
| New Indication(I-686) | Jun 29, 2017 |
| Orphan Drug Exclusivity(ODE) | Sep 24, 2017 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 17 June, 2009
Treatment: Treatment of macular edema; Intravitreal treatment of diabetic macular edema; Treatment of uveitis; Treatment of non-infectious uveitis affecting the posterior segment of the eye; Delivering an ocular...
Dosage: IMPLANT;INTRAVITREAL
OZURDEX family patents
40. Qulipta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(7 years from now) | |
| US8754096 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(8 years from now) | |
| US9850246 | ABBVIE | Process for making CGRP receptor antagonists |
Mar, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117836 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-909) | Apr 17, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: 28 September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: Preventive treatment of migraine in adults
Dosage: TABLET;ORAL
QULIPTA family patents
41. Rectiv patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7189761 | ABBVIE | Nitric oxide donor composition and method for treatment of anal disorders |
May, 2014
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 21, 2014 |
Drugs and Companies using NITROGLYCERIN ingredient
Market Authorisation Date: 21 June, 2011
Treatment: Rectiv is a nitrate vasodilator indicated for the treatment of moderate to severe pain associated with chronic anal fissure
Dosage: OINTMENT;INTRA-ANAL
RECTIV family patents
42. Restasis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5474979 | ABBVIE | Nonirritating emulsions for sensitive tissue |
May, 2014
(9 years ago) | |
| US8633162 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
| US8685930 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
| US8629111 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
| US8642556 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
| US8648048 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
| US9248191 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION;OPHTHALMIC
RESTASIS family patents
43. Restasis Multidose patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8685930 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
| US8648048 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
| US8633162 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
| US8629111 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
| US9248191 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
| US8642556 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
| US8292129 | ABBVIE | Dispensing device |
Feb, 2031
(6 years from now) | |
| US8561859 | ABBVIE | Dispensing device |
Apr, 2032
(7 years from now) | |
| US9676525 | ABBVIE | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
Feb, 2034
(9 years from now) | |
| US9669974 | ABBVIE | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
May, 2034
(10 years from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).; Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION;OPHTHALMIC
RESTASIS MULTIDOSE family patents
44. Rinvoq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE47221 | ABBVIE | Tricyclic compounds |
Dec, 2030
(6 years from now) | |
| US8962629 | ABBVIE | Tricyclic compounds |
Jan, 2031
(6 years from now) | |
| US11773105 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US9951080 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11661425 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US10981923 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11186584 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11718627 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11680069 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11780848 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11787815 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US10344036 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11365198 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US10981924 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11198697 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US10519164 | ABBVIE | Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11535625 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US10550126 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US10995095 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US10597400 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11780847 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11767326 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11524964 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11535626 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US10202393 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11535624 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US9963459 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11773106 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11795175 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US10730883 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11512092 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(12 years from now) | |
| US11607411 | ABBVIE | Methods of treating Crohn's disease and ulcerative colitis |
Mar, 2038
(13 years from now) | |
| US11564922 | ABBVIE | Methods of treating crohn's disease and ulcerative colitis |
Mar, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
| New Indication(I-919) | May 18, 2026 |
| New Indication(I-886) | Mar 16, 2025 |
| New Indication(I-888) | Apr 29, 2025 |
| New Indication(I-880) | Dec 14, 2024 |
| New Indication(I-883) | Jan 14, 2025 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active psoriatic arthritis who have had ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
RINVOQ family patents
45. Savella patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7888342 | ABBVIE | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
Nov, 2021
(2 years ago) | |
| US6992110 | ABBVIE | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
Nov, 2021
(2 years ago) | |
| US6602911 | ABBVIE | Methods of treating fibromyalgia |
Jan, 2023
(1 year, 3 months ago) | |
| US7994220 | ABBVIE | Milnacipran for the long-term treatment of fibromyalgia syndrome |
Sep, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 14, 2014 |
Drugs and Companies using MILNACIPRAN HYDROCHLORIDE ingredient
NCE-1 date: 14 January, 2013
Market Authorisation Date: 14 January, 2009
Treatment: Management of fibromyalgia (fm); Management of fibromyalgia
Dosage: TABLET;ORAL
SAVELLA family patents
46. Simcor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6406715 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles |
Sep, 2013
(10 years ago) | |
| US6676967 | ABBVIE | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
Sep, 2013
(10 years ago) | |
| US6818229 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
Sep, 2013
(10 years ago) | |
| US6746691 | ABBVIE | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
Sep, 2013
(10 years ago) | |
| US7998506 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
| US6129930 | ABBVIE | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
Sep, 2013
(10 years ago) | |
| US7011848 | ABBVIE | Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
Sep, 2013
(10 years ago) | |
| US6080428 | ABBVIE | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
May, 2017
(6 years ago) | |
| US6469035 | ABBVIE | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
Mar, 2018
(6 years ago) | |
Drugs and Companies using NIACIN; SIMVASTATIN ingredient
Market Authorisation Date: 15 February, 2008
Treatment: Adjunct to diet to reduce elevated total-c, ldl-c, non-hdl-c, apo b, tg, and lp(a) levels and to increase hdl-c in patients with primary hypercholesterolemia, mixed dyslipidemia, and hypertriglyceride...
Dosage: TABLET, EXTENDED RELEASE;ORAL
SIMCOR family patents
47. Tarka patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5721244 | ABBVIE | Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as their use in drugs |
Feb, 2015
(9 years ago) | |
Drugs and Companies using TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 1996
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
TARKA family patents
48. Technivie patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8642538 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(5 years from now) | |
| US8420596 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(6 years from now) | |
| US8691938 | ABBVIE | Anti-viral compounds |
Apr, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6703403 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
| US6037157 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
|
US6037157 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
|
US6703403 (Pediatric) | ABBVIE | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
| US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
|
US7148359 (Pediatric) | ABBVIE | Polymorph of a pharmaceutical |
Jan, 2020
(4 years ago) | |
| US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
|
US7364752 (Pediatric) | ABBVIE | Solid dispersion pharamaceutical formulations |
May, 2021
(2 years ago) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
|
US8399015 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
|
US8268349 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Feb, 2025
(9 months from now) | |
| US9006387 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US9044480 | ABBVIE | Compositions and methods for treating HCV |
Apr, 2031
(6 years from now) | |
| US8686026 | ABBVIE | Solid compositions |
Jun, 2031
(7 years from now) | |
|
US8420596 (Pediatric) | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Oct, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 24, 2018 |
| New Indication(I-743) | Jul 24, 2018 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 24 July, 2015
Treatment: Use of ritonavir as a potent cyp3a inhibitor to increase plasma drug concentration of paritaprevir and overall drug exposure for treatment of hcv infection; Treatment of hcv infection using ombitasvir...
Dosage: TABLET;ORAL
TECHNIVIE family patents
49. Teflaro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6906055 | ABBVIE | Phosphonocephem compound |
Dec, 2021
(2 years ago) | |
| US6417175 | ABBVIE | Phosphonocephem derivatives, process for the preparation of the same, and use thereof |
Apr, 2022
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7419973 | ABBVIE | Phosphonocephem compound |
Dec, 2021
(2 years ago) | |
| US9629861 | ABBVIE | Compositions and methods for treating bacterial infections using ceftaroline |
Sep, 2030
(6 years from now) | |
| US8247400 | ABBVIE | Cephem compounds useful for the treatment of bacterial infections |
Feb, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 13, 2022 |
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2015 |
Drugs and Companies using CEFTAROLINE FOSAMIL ingredient
NCE-1 date: 29 October, 2014
Market Authorisation Date: 29 October, 2010
Treatment: Method of treating bacterial infections; Methods for treating bacterial infections
Dosage: POWDER;INTRAVENOUS
TEFLARO family patents
50. Teveten patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5656650 | ABBVIE | Angiotensin II receptor blocking compositions |
Aug, 2014
(9 years ago) | |
Drugs and Companies using EPROSARTAN MESYLATE ingredient
Market Authorisation Date: 22 December, 1997
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
TEVETEN family patents
51. Teveten Hct patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5656650 | ABBVIE | Angiotensin II receptor blocking compositions |
Aug, 2014
(9 years ago) | |
Drugs and Companies using EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE ingredient
Market Authorisation Date: 01 November, 2001
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
TEVETEN HCT family patents
52. Tricor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6652881 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability |
Jan, 2018
(6 years ago) | |
| US6277405 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7041319 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailabilty |
Jan, 2018
(6 years ago) | |
| US6589552 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
| US7037529 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
| US6277405 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
| US6074670 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it |
Jan, 2018
(6 years ago) | |
| US6652881 | ABBVIE | Fenofibrate pharmaceutical composition having high bioavailability |
Jan, 2018
(6 years ago) | |
| US6375986 | ABBVIE | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
Sep, 2020
(3 years ago) | |
| US7276249 | ABBVIE | Nanoparticulate fibrate formulations |
Feb, 2023
(1 year, 2 months ago) | |
| US7320802 | ABBVIE | Methods of treatment using nanoparticulate fenofibrate compositions |
Feb, 2023
(1 year, 2 months ago) | |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 04 September, 2001
Treatment: Adjunctive therapy to diet in adults to reduce ldl-c, total-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to t...
Dosage: TABLET;ORAL
TRICOR family patents
53. Trilipix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7259186 | ABBVIE | Salts of fenofibric acid and pharmaceutical formulations thereof |
Jan, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2011 |
Drugs and Companies using CHOLINE FENOFIBRATE ingredient
Market Authorisation Date: 15 December, 2008
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE;ORAL
TRILIPIX family patents
54. Ubrelvy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(7 years from now) | |
| US8754096 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(8 years from now) | |
| US8912210 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Dec, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9833448 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(7 years from now) | |
| US10117836 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(10 years from now) | |
| US11717515 | ABBVIE | Treatment of migraine |
Dec, 2041
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: Acute treatment of migraine with or without aura in adults; Acute treatment of migraine with or without aura in a patient with severe hepatic impairment; Acute treatment of migraine with headache, wit...
Dosage: TABLET;ORAL
UBRELVY family patents
55. Ultane patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6288127 | ABBVIE | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jan, 2017
(7 years ago) | |
| US6444859 | ABBVIE | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jan, 2017
(7 years ago) | |
| US5990176 | ABBVIE | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jan, 2017
(7 years ago) | |
|
US6288127 (Pediatric) | ABBVIE | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jul, 2017
(6 years ago) | |
|
US6444859 (Pediatric) | ABBVIE | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jul, 2017
(6 years ago) | |
|
US5990176 (Pediatric) | ABBVIE | Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid |
Jul, 2017
(6 years ago) | |
| US6074668 | ABBVIE | Container for an inhalation anesthetic |
Jan, 2018
(6 years ago) | |
|
US6074668 (Pediatric) | ABBVIE | Container for an inhalation anesthetic |
Jul, 2018
(5 years ago) | |
Drugs and Companies using SEVOFLURANE ingredient
Market Authorisation Date: 07 June, 1995
Treatment: NA
Dosage: LIQUID;INHALATION
ULTANE family patents
56. Venclexta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8546399 | ABBVIE | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Jun, 2031
(7 years from now) | |
| US10730873 | ABBVIE | Salts and crystalline forms of an apoptosis-inducing agent |
Nov, 2031
(7 years from now) | |
| US8722657 | ABBVIE | Salts and crystalline forms of an apoptosis-inducing agent |
Jan, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9174982 | ABBVIE | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
May, 2030
(6 years from now) | |
| US11369599 | ABBVIE | Melt-extruded solid dispersions containing an apoptosis-inducing agent |
May, 2032
(8 years from now) | |
| US11110087 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(9 years from now) | |
| US9539251 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(9 years from now) | |
| US11590128 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
| US11413282 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
| US10993942 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-185) | Jun 08, 2025 |
| Orphan Drug Exclusivity(ODE-211) | Nov 21, 2025 |
| Orphan Drug Exclusivity(ODE-239) | May 15, 2026 |
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2021 |
| Orphan Drug Exclusivity(ODE) | Apr 11, 2023 |
| New Indication(I-789) | Nov 21, 2021 |
| New Indication(I-795) | May 15, 2022 |
| M(M-265) | Oct 16, 2023 |
| Orphan Drug Exclusivity(ODE-114) | Apr 11, 2023 |
| M(M-228) | Jun 08, 2021 |
| New Indication(I-782) | Jun 08, 2021 |
Drugs and Companies using VENETOCLAX ingredient
NCE-1 date: 11 April, 2020
Market Authorisation Date: 11 April, 2016
Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; Treatment of chroni...
Dosage: TABLET;ORAL
VENCLEXTA family patents
57. Viberzi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8609709 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
| US10213415 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
| US7786158 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
| US8691860 | ABBVIE | Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
| US9115091 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
| US7741356 | ABBVIE | Compounds as opioid receptor modulators |
May, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9205076 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
| US8344011 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
| US8772325 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
| US9700542 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
| US9364489 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
| US9789125 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
| US9675587 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US10188632 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11090291 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11160792 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11484527 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11311516 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11007179 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11229627 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2020 |
Drugs and Companies using ELUXADOLINE ingredient
NCE-1 date: 28 May, 2019
Market Authorisation Date: 27 May, 2015
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).; Reduction of the frequency of abdominal pain and diarrhea, in an inflammatory bowel disease with diarrhea (ibs-...
Dosage: TABLET;ORAL
VIBERZI family patents
58. Vicoprofen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6599531 | ABBVIE | Method of making ibuprofen and narcotic analgesic compositions |
Jun, 2017
(6 years ago) | |
| US6348216 | ABBVIE | Ibuprofen and narcotic analgesic compositions |
Jun, 2017
(6 years ago) | |
Drugs and Companies using HYDROCODONE BITARTRATE; IBUPROFEN ingredient
Market Authorisation Date: 23 September, 1997
Treatment: NA
Dosage: TABLET;ORAL
VICOPROFEN family patents
59. Viekira Pak (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501238 | ABBVIE | Anti-infective agents and uses thereof |
Dec, 2028
(4 years from now) | |
| US8188104 | ABBVIE | Anti-infective agents and uses thereof |
May, 2029
(5 years from now) | |
| US8642538 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(5 years from now) | |
| US8420596 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(6 years from now) | |
| US8691938 | ABBVIE | Anti-viral compounds |
Apr, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6037157 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
| US6703403 | ABBVIE | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
| US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
| US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US9139536 | ABBVIE | Anti-infective agents and uses thereof |
Nov, 2028
(4 years from now) | |
| US9006387 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US9044480 | ABBVIE | Compositions and methods for treating HCV |
Apr, 2031
(6 years from now) | |
| US8686026 | ABBVIE | Solid compositions |
Jun, 2031
(7 years from now) | |
| US8466159 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8492386 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8685984 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8680106 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US9629841 | ABBVIE | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(9 years from now) | |
| US10201542 | ABBVIE | Formulations of pyrimidinedione derivative compounds |
Oct, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Dosing Schedule(D-163) | Apr 22, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Use of ritonavir as a potent cyp3a inhibitor to increase plasma drug concentration of paritaprevir and overall drug exposure for treatment of hcv infection; Treatment of hcv infection using dasabuvir;...
Dosage: TABLET;ORAL
VIEKIRA PAK (COPACKAGED) family patents
60. Viekira Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501238 | ABBVIE | Anti-infective agents and uses thereof |
Sep, 2028
(4 years from now) | |
| US8188104 | ABBVIE | Anti-infective agents and uses thereof |
May, 2029
(5 years from now) | |
| US8642538 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Sep, 2029
(5 years from now) | |
| US8420596 | ABBVIE | Macrocyclic hepatitis C serine protease inhibitors |
Apr, 2031
(6 years from now) | |
| US8691938 | ABBVIE | Anti-viral compounds |
Apr, 2032
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7148359 | ABBVIE | Polymorph of a pharmaceutical |
Jul, 2019
(4 years ago) | |
| US7364752 | ABBVIE | Solid dispersion pharamaceutical formulations |
Nov, 2020
(3 years ago) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(3 months from now) | |
| US9139536 | ABBVIE | Anti-infective agents and uses thereof |
Nov, 2028
(4 years from now) | |
| US9006387 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
| US9044480 | ABBVIE | Compositions and methods for treating HCV |
Apr, 2031
(6 years from now) | |
| US8686026 | ABBVIE | Solid compositions |
Jun, 2031
(7 years from now) | |
| US10201584 | ABBVIE | Compositions and methods for treating HCV |
May, 2032
(8 years from now) | |
| US10201541 | ABBVIE | Compositions and methods for treating HCV |
May, 2032
(8 years from now) | |
| US8492386 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8685984 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8466159 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US8680106 | ABBVIE | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| US9744170 | ABBVIE | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | |
| US10105365 | ABBVIE | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | |
| US9333204 | ABBVIE | Solid antiviral dosage forms |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 22 July, 2016
Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using dasabuvir/ombitasvir/paritaprev...
Dosage: TABLET, EXTENDED RELEASE;ORAL
VIEKIRA XR family patents
61. Viibryd patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5532241 | ABBVIE | Piperidines and piperazines |
Sep, 2019
(4 years ago) | |
| US7834020 | ABBVIE | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(1 year, 10 months ago) | |
| US8673921 | ABBVIE | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(1 year, 10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8236804 | ABBVIE | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Jun, 2022
(1 year, 10 months ago) | |
| US8193195 | ABBVIE | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(1 year, 10 months ago) | |
|
US8193195 (Pediatric) | ABBVIE | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(1 year, 4 months ago) | |
|
US8236804 (Pediatric) | ABBVIE | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Dec, 2022
(1 year, 4 months ago) | |
|
US7834020 (Pediatric) | ABBVIE | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(1 year, 4 months ago) | |
|
US8673921 (Pediatric) | ABBVIE | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-146) | Mar 16, 2018 |
| M(M-254) | Jan 31, 2023 |
| Pediatric Exclusivity(PED) | Jul 31, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2016 |
Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2022
Market Authorisation Date: 21 January, 2011
Treatment: Treatment of major depressive disorder (mdd)
Dosage: TABLET;ORAL
VIIBRYD family patents
62. Vraylar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943621 | ABBVIE | Salts of piperazine compounds as D3/D2 antagonists |
Dec, 2028
(4 years from now) | |
| US7737142 | ABBVIE | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists |
Sep, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE49110 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(5 years from now) | |
| USRE49302 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(5 years from now) | |
| USRE47350 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-904) | Dec 16, 2025 |
| M(M-213) | Nov 09, 2020 |
| New Indication(I-798) | May 24, 2022 |
| New Chemical Entity Exclusivity(NCE) | Sep 17, 2020 |
Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient
NCE-1 date: 18 September, 2019
Market Authorisation Date: 17 September, 2015
Treatment: Adjunctive therapy to antidepressants for the treatment of major depressive disorder; Treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine
Dosage: CAPSULE;ORAL
VRAYLAR family patents
63. Vuity patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11285134 | ABBVIE | Presbyopia treatments |
Apr, 2039
(15 years from now) | |
| US10610518 | ABBVIE | Presbyopia treatments |
Apr, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-187) | Mar 28, 2026 |
| New Product(NP) | Oct 28, 2024 |
Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 October, 2021
Treatment: Use of vuity for the treatment of presbyopia in adults
Dosage: SOLUTION;OPHTHALMIC
VUITY family patents
64. Zemplar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5587497 | ABBVIE | 19-nor-vitamin D compounds |
Dec, 2013
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5246925 (Pediatric) | ABBVIE | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
Oct, 2012
(11 years ago) | |
| US5587497 | ABBVIE | 19-nor-vitamin D compounds |
Dec, 2013
(10 years ago) | |
|
US5587497 (Pediatric) | ABBVIE | 19-nor-vitamin D compounds |
Jun, 2014
(9 years ago) | |
| US5597815 | ABBVIE | Prevention of hyperphosphatemia in kidney disorder patients |
Jul, 2015
(8 years ago) | |
|
US5597815 (Pediatric) | ABBVIE | Prevention of hyperphosphatemia in kidney disorder patients |
Jan, 2016
(8 years ago) | |
| US6136799 | ABBVIE | Cosolvent formulations |
Apr, 2018
(6 years ago) | |
| US6361758 | ABBVIE | Cosolvent formulations |
Apr, 2018
(6 years ago) | |
|
US6361758 (Pediatric) | ABBVIE | Cosolvent formulations |
Oct, 2018
(5 years ago) | |
|
US6136799 (Pediatric) | ABBVIE | Cosolvent formulations |
Oct, 2018
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Oct 18, 2023 |
Drugs and Companies using PARICALCITOL ingredient
Market Authorisation Date: 01 February, 2000
Treatment: Prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (ckd) stage 5, which may result in renal osteodystrophy, while avoiding hyperphosphatemia
Dosage: SOLUTION;INTRAVENOUS; CAPSULE;ORAL
ZEMPLAR family patents
65. Zymaxid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5880283 | ABBVIE | 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same |
Dec, 2015
(8 years ago) | |
| US6333045 | ABBVIE | Aqueous liquid pharmaceutical composition comprised of gatifloxacin |
Aug, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5880283 (Pediatric) | ABBVIE | 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same |
Jun, 2016
(7 years ago) | |
|
US6333045 (Pediatric) | ABBVIE | Aqueous liquid pharmaceutical composition comprised of gatifloxacin |
Feb, 2020
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 18, 2013 |
Drugs and Companies using GATIFLOXACIN ingredient
Market Authorisation Date: 18 May, 2010
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
ZYMAXID family patents